ArticleBlood research2025

Real-world effectiveness and safety of rituximab and reduced-dose CHP with polatuzumab vedotin (pola-R-CHP) in patients aged > 80 years with diffuse large B-cell lymphoma: a retrospective analysis.

Shuku Sato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.